Exegiline
Exegiline is developing a novel oral drug, MT-31, for the treatment of the symptoms related to Alzheimer’s Disease. MT-31 structure combines Rivastigmine (Exelon) with Rasagiline’s (Azilect) propargyl moiety having unique beneficial properties. MT-31, its derivatives and indication, are protected by a recently granted US and EP patents.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
1
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Exegiline
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
Showing 1 of 1 verified contacts
Top roles at Exegiline
1 distinct titles indexed · top 1 shown.
- 1chairman-founder
Sign up to unlock all 1 contacts at Exegiline
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Exegiline
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.